These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 1378869)
1. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1. Kuroki M; Nakamura M; Itoyama Y; Tanaka Y; Shiraki H; Baba E; Esaki T; Tatsumoto T; Nagafuchi S; Nakano S J Immunol; 1992 Aug; 149(3):940-8. PubMed ID: 1378869 [TBL] [Abstract][Full Text] [Related]
2. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine. Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611 [TBL] [Abstract][Full Text] [Related]
3. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization. Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082 [TBL] [Abstract][Full Text] [Related]
4. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies. Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817 [TBL] [Abstract][Full Text] [Related]
5. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272 [TBL] [Abstract][Full Text] [Related]
6. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia. Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424 [TBL] [Abstract][Full Text] [Related]
7. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I. Edouard E; Legrand E; Astier-Gin T; Dalibart R; Geoffre S; Dalbon P; Guillemain B; Londos-Gagliardi D Leukemia; 1994 Apr; 8 Suppl 1():S60-4. PubMed ID: 7512182 [TBL] [Abstract][Full Text] [Related]
8. Association between maternal antibodies to the external envelope glycoprotein and vertical transmission of human T-lymphotropic virus type I. Maternal anti-env antibodies correlate with protection in non-breast-fed children. Hino S; Katamine S; Miyamoto T; Doi H; Tsuji Y; Yamabe T; Kaplan JE; Rudolph DL; Lal RB J Clin Invest; 1995 Jun; 95(6):2920-5. PubMed ID: 7769134 [TBL] [Abstract][Full Text] [Related]
9. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1. Jacobson S; Reuben JS; Streilein RD; Palker TJ J Immunol; 1991 Feb; 146(4):1155-62. PubMed ID: 1704032 [TBL] [Abstract][Full Text] [Related]
10. Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides. Londos-Gagliardi D; Jauvin V; Armengaut MH; Astier-Gin T; Goetz M; Huet S; Guillemain BJ AIDS Res Hum Retroviruses; 1999 Jul; 15(10):909-20. PubMed ID: 10408728 [TBL] [Abstract][Full Text] [Related]
11. [Identification of immunoreactive epitopes in proteins coded by gag, env, and pol genes of the type I human T-lymphotropic virus (HTLV-I) using synthetic peptides]. Iaroslavtseva NG; Ivanov VS; Grebennikova ZhO; Kornilaeva GV; Pashkova TA; Chikin LD; Ostrovskiĭ AG; Andreev SM; Khaitov RM; Karamov EV Bioorg Khim; 1995 Oct; 21(10):752-60. PubMed ID: 8573207 [TBL] [Abstract][Full Text] [Related]
12. [Immunoreactivity of synthetic peptides, corresponding to B-cellular epitopes of human type I T-lymphotrophic virus structural proteins]. Rasuli AM; Klepikov NN; Andreev SM; Sidorova MV; Vafina MG; Seniuta NB; Pavlish OA; Syrtsev AV; Gurtsevich VE Mol Biol (Mosk); 1993; 27(4):880-7. PubMed ID: 8361494 [TBL] [Abstract][Full Text] [Related]
13. Rapid syncytium formation between human T-cell leukaemia virus type-I (HTLV-I)-infected T-cells and human nervous system cells: a possible implication for tropical spastic paraparesis/HTLV-I associated myelopathy. Mor-Vaknin N; Turgeman H; Torgeman A; Wolfson M; Huleihel M; Aboud M Cell Biol Int; 1998; 22(2):95-103. PubMed ID: 9878096 [TBL] [Abstract][Full Text] [Related]
14. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation. Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594 [TBL] [Abstract][Full Text] [Related]
15. Humoral responses to the immunodominant gag and env epitopes of human T-lymphotropic virus type I among Melanesians. Lal RB; Rudolph DL; Nerurkar VR; Yanagihara R Viral Immunol; 1992; 5(4):265-72. PubMed ID: 1282011 [TBL] [Abstract][Full Text] [Related]
16. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. Horal P; Hall WW; Svennerholm B; Lycke J; Jeansson S; Rymo L; Kaplan MH; Vahlne A Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5754-8. PubMed ID: 1712105 [TBL] [Abstract][Full Text] [Related]
17. Identification of a novel neutralization epitope on envelope gp46 antigen of human T-cell-leukemia virus-type-II (HTLV-II). Tanaka Y; Tanaka R; Hoshino H Int J Cancer; 1994 Dec; 59(5):655-60. PubMed ID: 7525496 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I). Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859 [TBL] [Abstract][Full Text] [Related]
19. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I. Bélec L; Georges-Courbot MC; Georges A; Mohamed AS; Londos-Gagliardi D; Hallouin MC; Hocini H; Guillemain B J Med Virol; 1996 Sep; 50(1):42-9. PubMed ID: 8890040 [TBL] [Abstract][Full Text] [Related]
20. Human T lymphotropic virus types I- and II-specific antibody-dependent cellular cytotoxicity: strain specificity and epitope mapping. Zhang XQ; Yang L; Ho DD; Kuritzkes DR; Chen IS; Ching WT; Chen YM; Schooley RT J Infect Dis; 1992 May; 165(5):805-12. PubMed ID: 1373751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]